John F. Carpenter

发表

Meeting biopharmaceutical analytical requirements for subvisible particle sizing and counting

Christine Vessely, Amber Haynes Fradkin, John F. Carpenter, 2015 .

Analytical approaches to assess the degradation of therapeutic proteins

John F. Carpenter, Vasco Filipe, Andrea Hawe, 2013 .

Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation

John F. Carpenter, Theodore W. Randolph, J. Carpenter, 2003, Pharmaceutical Research.

Subvisible and Visible Particle Analysis in Biopharmaceutical Research and Development

John F. Carpenter, Andrea Hawe, J. Carpenter, 2015 .

The basis for toxicity of certain cryoprotectants: A hypothesis

John F. Carpenter, T. Arakawa, J. Carpenter, 1990 .

Some Lessons Learned From a Comparison Between Sedimentation Velocity Analytical Ultracentrifugation and Size Exclusion Chromatography to Characterize and Quantify Protein Aggregates.

John F. Carpenter, J. Carpenter, Aditya V. Gandhi, 2017, Journal of pharmaceutical sciences.

Contributions of local mobility and degree of retention of native secondary structure to the stability of recombinant human growth hormone (rhGH) in glassy lyophilized formulations

John F. Carpenter, Marcus T. Cicerone, Theodore W. Randolph, 2013 .

Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice

Michael J. Pikal, John F. Carpenter, Theodore W. Randolph, 1997, Pharmaceutical Research.

Thermal Stability of Low Molecular Weight Urokinase During Heat Treatment. II. Effect of Polymeric Additives

John F. Carpenter, M. Vrkljan, J. Henkin, 1994, Pharmaceutical Research.